Alkermes vs Corcept Therapeutics
Alkermes (ALKS), health care, and Corcept Therapeutics (CORT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alkermes and Corcept Therapeutics are valued at about the same: $7.6B and $7.8B. Alkermes's operating margin in its latest fiscal year was 17.2% and Corcept Therapeutics's 5.88%. Over the past year Alkermes's share price has moved +59.0% and Corcept Therapeutics's -7.84%.
Key facts
- Alkermes market value
- $7.6B
- Corcept Therapeutics market value
- $7.8B
- Corcept Therapeutics P/E
- 53.2
- Alkermes revenue
- $1.5BFY to 2025-12-31
- Corcept Therapeutics revenue
- $761.4MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Alkermes | Corcept Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.6Blower | $7.8Bhigher |
| Revenue | $1.5Bhigher | $761.4Mlower |
| Earnings | $241.7Mhigher | $99.7Mlower |
| Employees | 2,050higher | 730lower |
| Total assets | $2.5Bhigher | $836.7Mlower |
| Valuation | ||
| P/E | — | 53.2 |
| P/S | 5.2lower | 10.2higher |
| P/B | — | 9.3 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 17.2%higher | 5.88%lower |
| Balance sheet | ||
| Net assets | $1.8Bhigher | $647.8Mlower |
| Total liabilities | $667.7Mhigher | $188.8Mlower |
| Total debt | — | — |
| Cash on hand | $388.6Mhigher | $120.5Mlower |
| Price change | ||
| Today | -2.55%lower | +2.30%higher |
| 1 year | +59.0%higher | -7.84%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Jim Simons (1938–2024)0.4% / 0.8%
Alkermes only (3)
Corcept Therapeutics only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Alkermes / Corcept Therapeutics). Who owns ALKS · Who owns CORT
More on Alkermes
Further comparisons
Alkermes against its closest peers
Corcept Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Alkermes or Corcept Therapeutics?
By market value, Corcept Therapeutics is the larger: $7.8B against $7.6B for Alkermes. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $761.4M for Corcept Therapeutics.
Which has the higher operating margin?
Alkermes: 17.2%, against 5.88% for Corcept Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Alkermes and Corcept Therapeutics?
In their latest 13F filings, Jim Simons (1938–2024) holds both.
Cite this page
Funkfolio, “Alkermes vs Corcept Therapeutics”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-cort
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.